NovoCure Ltd
Company Stats
- Market Cap
- $1.9B
- as of Sep 30, 2026
- Shares Outstanding
- 116.4M
- Free Float
- 63.4%
Income Statement
- Revenue
- $655.4M
- Operating Income
- -$153.8M
- Net Income
- -$136.2M
- EBITDA
- -$144.4M
- Non-cash Impairment
- $4.9M
- Revenue Growth, 3Y
- 6.8%
- FCF Margin, 3Y Avg
- -14.2%
- FCF Margin, Worst Year
- -19.7%
Cash Flow
- Free Cash Flow
- -$75.7M
- FCF Yield
- -4.1%
- Owner FCF Yield
- -9.7%
Balance Sheet
- Cash & Equivalents
- $93.5M
Returns & Capital
- SBC, 3Y Avg
- $126.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $655.4M | -$75.7M | -11.5% |
| FY2024 | $605.2M | -$69.2M | -11.4% |
| FY2023 | $509.3M | -$100.4M | -19.7% |
| FY2022 | $537.8M | $9.4M | 1.8% |
| FY2021 | $535.0M | $58.6M | 11.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges